News Release

Pre clinical study shows empagliflozin reduces diabetic heart damage by preserving mitochondrial quality in rats

Pre clinical findings, not yet tested in patients, published in Cardiology Discovery offer new mechanistic clues for protecting against diabetic cardiomyopathy

Peer-Reviewed Publication

Chinese Medical Journals Publishing House Co., Ltd.

Schematic overview of the design for DM model establishment and EMPA intervention.

image: 

Type 2 diabetes was induced in Sprague-Dawley rats using a high-fat diet combined with a low dose of STZ. Diabetic rats were treated with low-dose EMPA (10 mg/kg daily) or high-dose EMPA (30 mg/kg daily) suspended in hydroxyethylcellulose via daily oral gavage. CON: Control; DM: Diabetes mellitus; EMPA: Empagliflozin; HFD: High-fat diet; STZ: Streptozotocin.

view more 

Credit: Cardiology Discovery

A pre‑clinical animal and cell‑based investigation published in Cardiology Discovery finds that empagliflozin, a sodium‑glucose cotransporter‑2 (SGLT‑2) inhibitor, limits pathological left‑heart remodeling in diabetic rats while improving cardiac mitochondrial function, offering new mechanistic understanding of this drug’s heart‑protective properties. This work is pre‑clinical finding, not ready for human clinical use, and seeks to explain why this diabetes drug lowers heart‑failure risk observed in large human clinical trials.

Diabetic cardiomyopathy is a serious diabetes‑related complication marked by heart muscle hypertrophy, fibrosis and diastolic dysfunction, which substantially elevates heart‑failure risk for patients with type‑2 diabetes. Large human trials confirm SGLT‑2 inhibitors reduce heart‑failure hospitalization risk for people with diabetes, but precisely how these agents shield the diabetic heart beyond blood‑sugar lowering remains incompletely characterized. Uncovering underlying molecular pathways could identify new targets for future cardiac therapies.

Researchers performed controlled animal experiments using high‑fat‑diet plus streptozotocin‑induced diabetic male Sprague‑Dawley rats, alongside high‑glucose‑exposed H9c2 rat cardiomyocyte cell tests. A total of 32 diabetic rats were randomized to receive vehicle, low‑dose empagliflozin (10 mg/kg daily), or high‑dose empagliflozin (30 mg/kg daily); an additional 8 non‑diabetic rats served as healthy controls, with 8 animals per final study group. Investigators delivered daily oral‑gavage treatment for 8 weeks, assessing cardiac structure, function, fibrosis, mitochondrial performance and key protein markers. Cellular experiments used gene knockdown and pharmacological inhibition to dissect signaling pathways.

Compared with untreated diabetic animals, empagliflozin‑treated diabetic rats displayed measurable reductions in cardiomyocyte enlargement and myocardial interstitial fibrosis (all P<0.05). Treated rats also demonstrated better diastolic hemodynamic indices and significant improvements in mitochondrial respiratory control ratio and mitochondrial membrane potential markers (both P<0.05). Diabetic myocardium showed depressed levels of sirtuin 1 (SIRT1) and PTEN‑induced kinase 1 (PINK1) proteins, which rose following empagliflozin intervention. Cell experiments confirmed blocking SIRT1 blunted these protein‑restoring effects, supporting SIRT1/PINK1 signaling as one contributing mechanism for empagliflozin‑linked cardiac protection.

Important study limitations must be emphasized. This work represents pre‑clinical rodent and cell‑culture research; findings cannot be directly translated to human patients. Only male rats were studied. Investigators did not directly measure mitophagic flux. The H9c2 cell line does not fully recapitulate adult human cardiomyocyte biology. The experimental diabetes model does not perfectly mirror human diabetic cardiomyopathy, and drug‑related blood‑pressure‑lowering effects may partially contribute to observed cardiac improvements. Future human studies are required to validate whether these molecular pathways operate within the human diabetic heart.

These experimental observations add mechanistic context to established real‑world cardiovascular benefits of empagliflozin, highlighting mitochondrial quality‑control pathways worthy of additional translational research.

Article citation: Cardiology Discovery, “Empagliflozin Attenuates Left Ventricular Remodeling in Diabetic Rats: Involvement of SIRT1/PINK1 Signaling.” DOI: 10.1097/CD9.0000000000000213


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.